In this study, a series of structurally novel N-(benzene sulfonyl) acetamide derivatives were designed, synthesized, and biologically evaluated as COX-2/5-LOX/TRPV1 multitarget inhibitors for anti-inflammatory and analgesic therapy. Among them, 9a and 9b displayed favorable COX-2 (9a IC=0.011 μM, 9b IC=0.023 μM), 5-LOX (9a IC=0.046 μM, 9b IC=0.31 μM) and TRPV1 (9a IC=0.008 μM, 9b IC=0.14 μM) inhibitory activities. The pharmacokinetic (PK) study of 9a in SD rats at the dosage of 10 mg/kg demonstrated a high oral exposure, an acceptable clearance and a favorable bioavailability (Cmax=5807.18 ± 2657.83 ng/mL, CL=3.24 ± 1.47 mL/min/kg, F=96.8%). Further in vivo efficacy studies illustrated that 9a was capable of ameliorating formalin-induced pain and inhibiting capsaicin-induced ear edema.
- Membership
 - Publications
 - Resources
 - Education
 - Event Calendar
 - Outreach
- Global Year
	
- Pain Management, Research and Education in Low- and Middle-Income Settings
 - Sex and Gender Disparities in Pain
 - Integrative Pain Care
 - Translating Pain Knowledge to Practice
 - Back Pain
 - Prevention of Pain
 - Pain in the Most Vulnerable
 - Pain Education
 - Joint Pain
 - Pain After Surgery
 - Global Year Campaign Archives
 
 - My Letter to Pain
 - IASP Statements
 - ICD-11 Pain Classification
 - National, Regional, and Global Pain Initiatives
 - International Pain Summit
 - Pain Awareness Month
 
 - Global Year
	
 - Careers
 - About
 - For Pain Patients and Professionals